Hims & Hers to Cease Sales of Weight Loss Pill

The evidence overwhelmingly supports the statement that Hims & Hers will cease sales of a specific weight loss pill. A strong consensus of high-authority, independent news organizations, including The New York Times, the Financial Times, and Bloomberg, directly report that Hims & Hers is withdrawing its newly launched compounded semaglutide (or "copycat Wegovy") pill. These reports consistently cite regulatory scrutiny and potential legal action as the reason for the decision, providing a credible explanation for the reversal.The sources that appear to contradict this are official press releases from Hims & Hers announcing the *launch* or *expansion* of its weight loss portfolio with this specific pill. However, these announcements do not contradict the subsequent decision to cease sales; instead, they establish a timeline of events where the product was launched and then quickly pulled from the market. The statement refers to "its weight loss pill" (singular), which accurately reflects the reporting about the discontinuation of this specific product, not the company's entire weight loss business. The weight and consistency of the multiple news reports about the cessation of sales far outweigh the initial launch announcements.